KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Cash from Operations (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Cash from Operations for 16 consecutive years, with 219029000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Operations rose 22.73% to 219029000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 651558000.0, a 36.01% increase, with the full-year FY2025 number at 651558000.0, up 36.01% from a year prior.
  • Cash from Operations was 219029000.0 for Q4 2025 at Halozyme Therapeutics, up from 178597000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 219029000.0 in Q4 2025 to a low of 36889000.0 in Q2 2021.
  • A 5-year average of 102937150.0 and a median of 93337500.0 in 2023 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: surged 1900.97% in 2021, then crashed 42.8% in 2022.
  • Halozyme Therapeutics' Cash from Operations stood at 82516000.0 in 2021, then fell by 0.08% to 82453000.0 in 2022, then rose by 24.14% to 102354000.0 in 2023, then surged by 74.36% to 178467000.0 in 2024, then increased by 22.73% to 219029000.0 in 2025.
  • Per Business Quant, the three most recent readings for HALO's Cash from Operations are 219029000.0 (Q4 2025), 178597000.0 (Q3 2025), and 99711000.0 (Q2 2025).